WO2000078396A3 - Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux - Google Patents

Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux Download PDF

Info

Publication number
WO2000078396A3
WO2000078396A3 PCT/US2000/006890 US0006890W WO0078396A3 WO 2000078396 A3 WO2000078396 A3 WO 2000078396A3 US 0006890 W US0006890 W US 0006890W WO 0078396 A3 WO0078396 A3 WO 0078396A3
Authority
WO
WIPO (PCT)
Prior art keywords
topical ophthalmic
mast cell
eye diseases
treating allergic
cell stabilizers
Prior art date
Application number
PCT/US2000/006890
Other languages
English (en)
Other versions
WO2000078396A2 (fr
Inventor
Gustav Graff
John M Yanni
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Priority to DK00917998T priority Critical patent/DK1187617T3/da
Priority to AU38883/00A priority patent/AU770975B2/en
Priority to CA002374002A priority patent/CA2374002A1/fr
Priority to JP2001504456A priority patent/JP4851035B2/ja
Priority to EP00917998A priority patent/EP1187617B1/fr
Priority to DE60008730T priority patent/DE60008730T2/de
Priority to AT00917998T priority patent/ATE260660T1/de
Publication of WO2000078396A2 publication Critical patent/WO2000078396A2/fr
Publication of WO2000078396A3 publication Critical patent/WO2000078396A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Cette invention a permis d'identifier des médicaments anti-allergiques ophtalmiques topiques grâce à l'étendue de leur interaction avec une membrane modèle de phospholipides. Cette invention concerne des formulations ophtalmiques à administration topique, contenant des composés anti-allergiques amphipathiques à des concentrations telles que ces médicaments présentent des indices d'activité de surface compris entre environ 2 et 11.
PCT/US2000/006890 1999-06-18 2000-03-16 Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux WO2000078396A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK00917998T DK1187617T3 (da) 1999-06-18 2000-03-16 Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
AU38883/00A AU770975B2 (en) 1999-06-18 2000-03-16 Topical ophthalmic mast cell stabilizers for treating allergic eye diseases
CA002374002A CA2374002A1 (fr) 1999-06-18 2000-03-16 Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux
JP2001504456A JP4851035B2 (ja) 1999-06-18 2000-03-16 アレルギー性眼疾患を処置するための局所的な眼マスト細胞安定剤
EP00917998A EP1187617B1 (fr) 1999-06-18 2000-03-16 Methode pour selectionner la concentration d'un compose amphipathique et antihistaminique par determination du taux d' activite de surface du compose
DE60008730T DE60008730T2 (de) 1999-06-18 2000-03-16 Methode zur konzentrationsbestimmung einer amphipathischen antihistaminischen verbindung durch bestimmung ihrer oberflächen aktivitäts einstufung
AT00917998T ATE260660T1 (de) 1999-06-18 2000-03-16 Methode zur konzentrationsbestimmung einer amphipathischen antihistaminischen verbindung durch bestimmung ihrer oberflächen aktivitäts einstufung

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13994599P 1999-06-18 1999-06-18
US60/139,945 1999-06-18
US15817799P 1999-10-07 1999-10-07
US60/158,177 1999-10-07

Publications (2)

Publication Number Publication Date
WO2000078396A2 WO2000078396A2 (fr) 2000-12-28
WO2000078396A3 true WO2000078396A3 (fr) 2001-08-16

Family

ID=26837695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006890 WO2000078396A2 (fr) 1999-06-18 2000-03-16 Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux

Country Status (11)

Country Link
US (1) US6420399B1 (fr)
EP (1) EP1187617B1 (fr)
JP (1) JP4851035B2 (fr)
AT (1) ATE260660T1 (fr)
AU (1) AU770975B2 (fr)
CA (1) CA2374002A1 (fr)
DE (1) DE60008730T2 (fr)
DK (1) DK1187617T3 (fr)
ES (1) ES2213001T3 (fr)
PT (1) PT1187617E (fr)
WO (1) WO2000078396A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883717B2 (en) 2001-06-12 2011-02-08 Johns Hopkins University Reservoir device for intraocular drug delivery
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US8101654B2 (en) * 2005-07-08 2012-01-24 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG2014007389A (en) 2009-01-29 2014-04-28 Forsight Vision4 Inc Posterior segment drug delivery
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
SI2600930T1 (sl) 2010-08-05 2021-08-31 Forsight Vision4, Inc. Injekcijska naprava za dajanje zdravila
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
EP2640360A2 (fr) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Formulations d'agents thérapeutiques pour des dispositifs implantés
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
EP4249059A3 (fr) 2011-06-28 2023-11-29 ForSight Vision4, Inc. Un appareil pour collecter un échantillon de fluide à partir d'une chambre réservoir d'un dispositif thérapeutique pour l'oeil
EP2739252A4 (fr) 2011-08-05 2015-08-12 Forsight Vision4 Inc Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
MX2017000609A (es) 2014-07-15 2017-04-27 Forsight Vision4 Inc Dispositivo y metodo de entrega de implante ocular.
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
KR20170106298A (ko) 2014-11-10 2017-09-20 포사이트 비젼4, 인크. 확장 가능한 약물 전달 장치 및 이용 방법
BR112018010063A2 (pt) 2015-11-20 2018-11-13 Forsight Vision4 Inc estruturas porosas para dispositivos de administração de medicamento de liberação estendida
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
JP7314155B2 (ja) 2017-11-21 2023-07-25 フォーサイト・ビジョン４・インコーポレーテッド 膨張可能ポート送達システムのための流体交換装置及びその使用方法
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
EP0433766A1 (fr) * 1989-12-18 1991-06-26 Alcon Laboratories, Inc. Composition d'anti-allergiques et d'anti-histaminiques et procédé pour leur application
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
WO1998042353A1 (fr) * 1997-03-25 1998-10-01 Allegheny University Of The Health Sciences Modulation de l'activation du mastocyte humain
WO1998056381A1 (fr) * 1997-06-09 1998-12-17 Bridge Pharma, Inc. Composes a combinaison d'activites antihistaminique et stabilisatrice des membranes cellulaires de mastocytes, utilises a des fins ophtalmiques
WO2000003705A1 (fr) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Utilisation d'acide 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz£b,e]oxepine-2-acetique dans la production d'un medicament de traitement de troubles ophtalmiques inflammatoires non allergiques et de prevention de la neoformation de vaisseaux sanguins oculaires
WO2000018731A1 (fr) * 1998-09-25 2000-04-06 Astrazeneca Ab Nouveaux composes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778814A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one
EP0433766A1 (fr) * 1989-12-18 1991-06-26 Alcon Laboratories, Inc. Composition d'anti-allergiques et d'anti-histaminiques et procédé pour leur application
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
WO1998042353A1 (fr) * 1997-03-25 1998-10-01 Allegheny University Of The Health Sciences Modulation de l'activation du mastocyte humain
WO1998056381A1 (fr) * 1997-06-09 1998-12-17 Bridge Pharma, Inc. Composes a combinaison d'activites antihistaminique et stabilisatrice des membranes cellulaires de mastocytes, utilises a des fins ophtalmiques
WO2000003705A1 (fr) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Utilisation d'acide 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz£b,e]oxepine-2-acetique dans la production d'un medicament de traitement de troubles ophtalmiques inflammatoires non allergiques et de prevention de la neoformation de vaisseaux sanguins oculaires
WO2000018731A1 (fr) * 1998-09-25 2000-04-06 Astrazeneca Ab Nouveaux composes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DESCHENEST J ET AL: "Assessment of the efficacy of olopatadine ophthalmic solution (0.1 percent) and ketorolac ophthalmic solution (0.5 percent) in the allergen challenge model.", IOVS, vol. 39, no. 4, 15 March 1998 (1998-03-15), Annual Meeting of the Association for Research in Vision and Ophthalmology;Fort Lauderdale, Florida, USA; May 10-15, 1998, pages S549, XP000980214 *
GIOVANONI A ET AL: "Patanol is superior to claritin in reducing ocular itching of allergic conjunctivitis using the provocative antigen challenge model.", IOVS, vol. 40, no. 4, 15 March 1999 (1999-03-15), Annual Meeting of the Association for Research in Vision and Ophthalmology;Fort Lauderdale, Florida, USA; May 9-14, 1999, pages S684, XP000980213 *
SHARIF N A ET AL: "CHARACTERIZATION OF THE OCULAR ANTIALLERGIC AND ANTIHISTAMINIC EFFECTS OF OLOPATADINE (AL-4943A), A NOVEL DRUG FOR TREATING OCULAR ALLERGIC DISEASES", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,US,AMERICAN SOCIETY FOR PHARMACOLOGY AND, vol. 278, no. 3, 1 September 1996 (1996-09-01), pages 1252 - 1261, XP000613049, ISSN: 0022-3565 *
SHARIF N A ET AL: "Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: Role in ocular allergic and inflammatory diseases.", EXPERIMENTAL EYE RESEARCH, vol. 63, no. 2, 1996, pages 169 - 178, XP000980208, ISSN: 0014-4835 *
UDELL I J ET AL: "ANIMAL AND HUMAN OCULAR SURFACE RESPONSE TO A TOPICAL NONIMMUNE MAST CELL DE GRANULATING AGENT COMPOUND 48-80", AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 91, no. 2, 1981, pages 226 - 230, XP000980212, ISSN: 0002-9394 *
VERIN P: "Treating severe eye allergy.", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 28, no. SUPPL. 6, December 1998 (1998-12-01), pages 44 - 48, XP000980220, ISSN: 0954-7894 *
WEIMER L K ET AL: "Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: Inhibition by the histamine H1 antagonist emedastine.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 115, no. 4, April 1998 (1998-04-01), pages 288 - 293, XP000980217, ISSN: 1018-2438 *
YANNI J M ET AL: "A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: Effects of new topical ocular drugs.", ACTA OPHTHALMOLOGICA SCANDINAVICA SUPPLEMENT, no. 228, 1999, pages 33 - 37, XP000980225, ISSN: 1395-3931 *

Also Published As

Publication number Publication date
EP1187617B1 (fr) 2004-03-03
JP2003502393A (ja) 2003-01-21
AU3888300A (en) 2001-01-09
DK1187617T3 (da) 2004-04-13
JP4851035B2 (ja) 2012-01-11
ATE260660T1 (de) 2004-03-15
AU770975B2 (en) 2004-03-11
WO2000078396A2 (fr) 2000-12-28
PT1187617E (pt) 2004-06-30
US6420399B1 (en) 2002-07-16
DE60008730D1 (de) 2004-04-08
EP1187617A2 (fr) 2002-03-20
DE60008730T2 (de) 2004-08-05
CA2374002A1 (fr) 2000-12-28
ES2213001T3 (es) 2004-08-16

Similar Documents

Publication Publication Date Title
WO2000078396A3 (fr) Stabilisateur de mastocytes a usage ophtalmique topique, pour traiter les affections allergiques des yeux
Wang et al. Differential impairment of spatial and nonspatial cognition in a mouse model of brain aging
EP1535915A4 (fr) Derive de furane ou de thiophene, et ses utilisations pharmaceutiques
NO970517L (no) Topiske oftalmiske formuleringer inneholdende doxepinderivater for behandling av öyenallergisykdommer
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
DE60100866D1 (de) Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel
CA2447924A1 (fr) Formulations d'olopatadine a administration topique
EP0249735A3 (fr) Préparations pharmaceutiques contenant comme agent actif la 2-phényl-1,2-benzisosélénazol-3(2H)-one, pour le traitement des maladies causées par le stress oxydant
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
Koh et al. Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: bridging Niemann–Pick disease type C and Alzheimer's disease
WO2004089380A3 (fr) Utilisation pharmaceutique de 1,2,4-triazoles fusionnes
Anselmi et al. Conformational analysis: a tool for the elucidation of the antioxidant properties of ferulic acid derivatives in membrane models
KR950031065A (ko) 지방산 유도체
ES2878063T3 (es) Derivados de la alfa-aminoamida para el tratamiento de trastornos psiquiátricos
EP1202723A2 (fr) Utilisation topique d'agents anti-muscarinique
Li et al. Protective effects and mechanism of tetramethylpyrazine against lens opacification induced by sodium selenite in rats
ATE419864T1 (de) Therapie von erkrankungen des auges
ES2191762T3 (es) Uso de derivados del acido sulfamico, de acil sulfonamidas o de sulfonil carbamatos para la preparacion de un medicamento para reducir los niveles de lipoproteinas.
Knodel Current issues in drug toxicity potential health hazards of sulfites
Nagai et al. Inhibitive effects of enhanced lipid peroxidation on Ca2+-ATPase in lenses of hereditary cataract ICR/f rats
Gerencser et al. Effect of binding of Cd2+ on bacterial reaction center mutants: proton-transfer uses interdependent pathways
NO179632C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat som inneholder podofyllotoksin
ATE275953T1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
DE60012494D1 (de) Herstellung von substituierten aromatischen carbonsaüreestern
FI980947A0 (fi) Zeaksantiinin puhdas 3R-3'R-stereoisomeeri silmän keltatäplämuutoksen hoitamiseksi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000917998

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2374002

Country of ref document: CA

Ref country code: CA

Ref document number: 2374002

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 38883/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 504456

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000917998

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000917998

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 38883/00

Country of ref document: AU